Generic Drug Therapeutic Class: Neurology-Psychiatry
active ingredients: Meclozine
laboratory: Ucb Pharma SA
Box of 15
Symptomatic treatment of the vertiginous crisis.
Prevention and treatment of motion sickness.
Dosage AGYRAX 25 mg scored tablet Box of 15
Vertiginous crisis :
1 to 3 tablets daily to be taken before meals.
Swallow without chewing with a little water or another soft drink.
Motion sickness :
The first dose should be made 1 hour before the trip: 1 to 4 tablets per day.
Pediatric population: There are no data in children and adolescents
· Hypersensitivity to meclozine, any of the components of the product, or to any of the piperazine derivatives
· Hepatic impairment (see section Pharmacokinetic properties )
· Linked to the anticholinergic effect:
o Risk of glaucoma by closing the angle
o Risk of urinary retention related to urethroprostatic disorders.
Agyrax side effects
Adverse effects of AGYRAX are mainly related to its action on the central nervous system, its anticholinergic effects and the hypersensitivity reactions it can cause. They are listed below by organ class. The most common side effects that are considered to be the most common are drowsiness or sedation. Dryness of the mouth is a common side effect. Blurred vision, nausea and vomiting rarely occur.
Cardiac disorders: palpitations, tachycardia
Affections of the ear and labyrinth : tinnitus, vertigo
Eye disorders : diplopia, blurred vision
Gastrointestinal disorders : abdominal pain, constipation, diarrhea, dry mouth, nausea, vomiting
General disorders : tiredness, weakness
Immune system disorders : anaphylactic shock.
Investigations: weight gain
Metabolism and nutrition disorders : anorexia, increased appetite
Nervous system disorders : dizziness, headache, paresthesia, sedation, drowsiness, movement disorders (including Parkinson's syndrome)
Psychiatric disorders : anxiety, euphoric mood, excitability, hallucinations, insomnia, psychotic disorders, memory problems, disorientation, confusion and paranoia.
Renal and urinary disorders : dysuria, polyuria, urinary retention
Respiratory, thoracic and mediastinal disorders : dry throat, nasal dryness
Vascular disorders : hypotension
Skin and subcutaneous tissue disorders : rash, urticaria.
Reporting of suspected adverse reactions
The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the drug. Health professionals report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centers. www.ansm.sante.fr.